MAR 31, 2019 08:34 PM PDT

Glowing Tumors Reveal How Immunotherapeutics Work

WRITTEN BY: Nouran Amin

In a study published in the Journal of Clinical Investigation, researchers used positron emission tomography (PET) scans to examine how an immunotherapy drug reaches a tumor and the parts of a cancer that remain unaffected.

Learn more about how PET scans work:

The process of PET imaging uses a synthesized radiolabeled protein that locks on to tumor cells—this allows researchers to visually follow where the so-called checkpoint inhibitor drug binds to a tumor. "This approach offers a vital step toward directly measuring how well immunotherapy drugs are able to engage a tumor in any given person," says Sridhar Nimmagadda, Ph.D., associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine and a member of the Sidney Kimmel Comprehensive Cancer Center.

Radiolabeled protein lights up tumor implanted in the arm of a mouse under a PET scan. The researchers hope to use scans like this one to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of a cancer remain unaffected. Credit: Sridhar Nimmagadda via John Hopkins

If PET imaging precision is confirmed to be highly effective in additional tests, it could streamline cancer therapy by enhancing the therapeutic dose of a drug. The use of checkpoint inhibitors is a form of cancer therapy designed to help the immune systems recognize cancer cells and to target them. For example, the programmed death ligand 1 (PD-L1) is one such checkpoint target by three approved therapeutics called atezolizumab, avelumab and durvalumab by the U.S. Food and Drug Administration (FDA).

In the study, researchers created a radiolabeled small protein that binds to PD-L1 which facilitates marking its receptor with a radiotracer seen with PET imaging technique. "In human patients, this could give us some insight about how to optimize further treatments by increasing the dose or substituting other drugs or therapies more quickly,” says Nimmagadda.

Source: John Hopkins School of Medicine

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 14, 2019
Drug Discovery & Development
NOV 14, 2019
Does TruBrain Really Work?
TruBrain is a mix of different substances claimed to help people increase verbal fluency, avoid distractions, and boost their mental output. Created by a t...
NOV 14, 2019
Drug Discovery & Development
NOV 14, 2019
Injectable Implant Drug Shows Promise for HIV Treatment
In a study published in Nature Communications, alternative treatment was shown to have promising results for HIV as opposed to a daily pill regimen. Scient...
NOV 14, 2019
Cannabis Sciences
NOV 14, 2019
CBD Extract for Cannabis Addiction
Some people believe the secret to curing a hangover is to drink more alcohol the morning after a night of binge drinking - “the hair of the dog that...
NOV 14, 2019
Technology
NOV 14, 2019
Machine-Learning and Epigenetics Drug Discovery
Machine learning is known for detecting patterns seen in complex data—such uniqueness has proven it roles in health and medicine. Now, researchers at...
NOV 14, 2019
Drug Discovery & Development
NOV 14, 2019
Treating Gulf-War Illness with Anti-Viral Drugs
Researchers at the University of South Carolina's Arnold School of Public Health have reported that repurposing existing FDA-approved antiviral drugs o...
NOV 14, 2019
Neuroscience
NOV 14, 2019
Suicidal Mitochondria Responsible for ALS
Scientists at Northwestern University have dicovered a new mechanism in the brain that may be responsable for the early stages of neurodegeneration seen in...
Loading Comments...